Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
Want to see JP:4577 full AI Analyst Report?
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥970.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)63.87K
Market Cap
¥41.04B
Enterprise Value¥47.63B
Total Cash (Recent Filing)¥2.15B
Total Debt (Recent Filing)¥11.94B
Price to Earnings (P/E)10.4
Beta0.26
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)35.21
Shares Outstanding30,096,880
10 Day Avg. Volume54,390
30 Day Avg. Volume63,866
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)0.58
Price to Sales (P/S)0.59
P/FCF Ratio-31.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing & API FocusDaito's core business as a contract manufacturer and API supplier creates durable, fee-based revenue streams from third-party customers and branded/generic clients. Long-term demand for validated manufacturing capacity and regulatory-compliant supply chains supports stable utilization and predictable backlog.
Consistent Revenue GrowthSustained top-line growth indicates expanding market share or higher contract volumes, which is important for amortizing fixed manufacturing capacity. Continued revenue increases over years improve capacity utilization and provide a platform for margin recovery if cost control follows.
Stable Equity Ratio / Solid Capital BaseA stable equity ratio signals a resilient capital structure that cushions operational variability common in pharma manufacturing. This structural strength supports access to capital for capacity investments and regulatory compliance without immediate dilution of shareholder claims.
Bears Say
Rising LeverageLeverage rising materially from very low levels reduces financial flexibility and increases fixed obligations. In a capital-intensive manufacturing business, higher debt amplifies risk if revenue or margins weaken, constraining investment ability and raising refinancing exposure over the medium term.
Declining Profit MarginsMaterial margin compression across gross and net lines suggests pricing pressure or rising input and operating costs. Persistently lower margins erode the company's ability to self-fund growth and reduce returns on invested capital, undermining long-term profitability and shareholder returns.
Negative Free Cash Flow TrendSustained negative free cash flow limits the company's capacity to invest, pay down debt, or maintain dividends without external financing. For a manufacturer facing margin pressure and higher leverage, constrained cash generation is a structural concern for executing strategic initiatives and absorbing shocks.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥970.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥41.04B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date is Jul 10, 2026 which is in 80 days.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Daito Pharmaceutical Co., Ltd. released its earnings results on Apr 10, 2026. The company reported ¥35.21 earnings per share for the quarter, beating the consensus estimate of N/A by ¥35.21.
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 2.75%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 30,096,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daito Pharmaceutical Co., Ltd. reported an EPS of ¥35.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.095%.
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---